SGR-2921

SGR-2921 is an orally bioavailable, selective, tight-binding small molecule inhibitor of cell division cycle 7-related protein kinase (CDC7), developed by Schrödinger for the treatment of hematological malignancies. CDC7 is a serine/threonine kinase that plays a critical role in cell cycle regulation and DNA replication. Inhibition of CDC7 impairs the replication stress response in cancer cells, leading to accumulation of DNA damage and cell death. SGR-2921 has demonstrated significant anti-leukemic activity in preclinical models, including those resistant to standard therapies, and is currently being evaluated as monotherapy and in combination with other agents for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The drug has received Orphan Drug status and Fast Track designation from the FDA for AML[1][3][4][5][6].